- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Real-World Data on XARELTO® in Patients with Non-Valvular Atrial Fibrillation and Diabetes Among 14 Presentations at American College of Cardiology’s 65th Annual Scientific Session
New data add to growing body of real-world evidence supporting physicians and hospitals in optimizing patient care for those at risk of stroke or blood clots
Real-World Study Found XARELTO® Led to Cost Savings and Shorter Stays in U.S. Hospitals Compared to Warfarin When Used for Treatment of Blood Clots
Findings from this cost savings analysis add to research confirming value of XARELTO® (rivaroxaban) in reducing cost burden to healthcare systems
First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI
Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination
Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections
New approach for early treatment and interception of HPV-induced cancers
First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer
First of Nine Studies, Examining the Ability of Rivaroxaban to Reduce the Burden of Cancer-Associated Blood Clots, Presented at ASH Annual Meeting
Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis
XALIA is First Prospective Study to Confirm Benefit of a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) for Treating Deep Vein Thrombosis in Routine Clinical Practice, Adds to More than 91,000 Patients Enrolled in Real-World Studies
DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent
Largest Schizophrenia and Schizoaffective Disorder Caregiver Survey Reveals Overwhelming Burden and Inadequate Assistance
Findings Highlight Need for Education and More Support for Caregivers